Harbin Jixianglong semaglutide recalled for incomplete manufacturing validation
Harbin Jixianglong Biotech distributed semaglutide (an injectable medication for compounding) without completing required manufacturing process and bacterial endotoxin testing. This means the drug may not meet safety and purity standards. The affected lot is CP-030-20250711 with an expiration date of July 24, 2027.
From the FDA notice · Read the official notice ↗
What to do
- If you have semaglutide from Harbin Jixianglong with lot CP-030-20250711, stop using it immediately.
- Contact your pharmacist or healthcare provider for guidance on next steps.
- Do not discard medication in the trash or toilet; ask your pharmacy how to safely dispose of it.
Is yours affected?
Compare your label or packaging with the recalled product.
- Product
- Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04 Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China
- Sold in
- Nationwide
- Made for
- All ages (0 months and older)
This recall covers 2 products — see all of them.
Details
- Units affected
- N/A
- Illnesses reported
- None reported
- Manufactured in
- North Of Baoan Road, East Of Changqing Street, Hulan District, Haerbin, N/A, China
- Classification
- Class II
- Recall number
- D-0379-2026
In the FDA's words
- Description
- Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04 Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution Lot #: CP-030-20250711, Exp. Date Jul. 24th, 2027 Distribution: Nationwide within the United States Affected quantity: N/A
- Hazard
- CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution
2 products in this recall
The agency lists each product separately. Check every one you might have.
- Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d… (this page)D-0379-2026 · N/A
- Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03;…D-0380-2026 · N/A